171 related articles for article (PubMed ID: 27249598)
1. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells.
Li L; Xu QH; Dong YH; Li GX; Yang L; Wang LW; Li HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):2004-10. PubMed ID: 27249598
[TBL] [Abstract][Full Text] [Related]
2. KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
Feng T; Wang Y; Lang Y; Zhang Y
Mol Med Rep; 2017 Sep; 16(3):3573-3580. PubMed ID: 28714030
[TBL] [Abstract][Full Text] [Related]
3. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
4. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
6. MiR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2.
Zhiping C; Shijun T; Linhui W; Yapei W; Lianxi Q; Qiang D
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4835-4843. PubMed ID: 29164579
[TBL] [Abstract][Full Text] [Related]
7. miRNA-181a inhibits the proliferation, migration, and epithelial-mesenchymal transition of lens epithelial cells.
Dong N; Tang X; Xu B
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):993-1001. PubMed ID: 25626972
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
Yu JL; Gao X
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
[TBL] [Abstract][Full Text] [Related]
9. MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells.
Li C; Zou J; Zheng G; Chu J
Med Sci Monit; 2016 Nov; 22():4509-4515. PubMed ID: 27876712
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
Wang B; Li S; Meng X; Shang H; Guan Y
Tumour Biol; 2015 Aug; 36(8):6433-43. PubMed ID: 25801244
[TBL] [Abstract][Full Text] [Related]
11. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
12. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
13. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway.
Wang B; Li X; Zhao G; Yan H; Dong P; Watari H; Sims M; Li W; Pfeffer LM; Guo Y; Yue J
J Exp Clin Cancer Res; 2018 Sep; 37(1):235. PubMed ID: 30241553
[TBL] [Abstract][Full Text] [Related]
14. Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.
Xu M; Zhou K; Wu Y; Wang L; Lu S
Mol Carcinog; 2019 Apr; 58(4):577-587. PubMed ID: 30556928
[TBL] [Abstract][Full Text] [Related]
15. MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance.
Luan QX; Zhang BG; Li XJ; Guo MY
Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4257-4265. PubMed ID: 27831649
[TBL] [Abstract][Full Text] [Related]
16. Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial-mesenchymal transition.
Yu J; Han Q; Cui Y
Tumour Biol; 2017 Jul; 39(7):1010428317709129. PubMed ID: 28691641
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
18. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail.
Ding JX; Feng YJ; Yao LQ; Yu M; Jin HY; Yin LH
Gynecol Oncol; 2006 Nov; 103(2):623-30. PubMed ID: 16806441
[TBL] [Abstract][Full Text] [Related]
19. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
20. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
